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EssentialsBetter biomarkers are needed to predict cancer‐associated thrombosis.We identified RNA expression profiles in patients with lung cancer with and without thrombosis.Identified genes and pathways involved in inflammation, KRAS, and innate immunity associated with thrombosis in patients with lung cancer.These differentially expressed genes may promote development of new risk stratification and therapeutic strategies.

1. INTRODUCTION {#rth212284-sec-0007}
===============

The risk of venous thromboembolism (VTE) is increased in patients with cancer, by at least 4‐ to 7‐fold.[1](#rth212284-bib-0001){ref-type="ref"}, [2](#rth212284-bib-0002){ref-type="ref"} VTE significantly contributes to morbidity and a worse overall prognosis in patients with cancer.[3](#rth212284-bib-0003){ref-type="ref"} VTE incidences ranging from 2% to 14% have been reported in different populations of patients with cancer, with the highest VTE risk identified in patients with pancreatic (\~11%), lung (\~8%), and stomach cancer (\~8%).[1](#rth212284-bib-0001){ref-type="ref"}, [2](#rth212284-bib-0002){ref-type="ref"}, [3](#rth212284-bib-0003){ref-type="ref"}, [4](#rth212284-bib-0004){ref-type="ref"} Patients with lung cancer have an elevated risk of VTE compared to other malignancies, with incidence rates ranging from 7% to 15%.[4](#rth212284-bib-0004){ref-type="ref"}, [5](#rth212284-bib-0005){ref-type="ref"}, [6](#rth212284-bib-0006){ref-type="ref"} Various clinical predictors for increased VTE risk have been identified; however, further understanding of thrombogenic biomarkers is needed.

The pathophysiology of cancer‐associated VTE involves complex interactions among the tumor (oncogenes and proteins), intracellular signaling pathways, coagulation system, and anticancer treatment.[7](#rth212284-bib-0007){ref-type="ref"}, [8](#rth212284-bib-0008){ref-type="ref"}, [9](#rth212284-bib-0009){ref-type="ref"} A validated risk model for VTE has been developed based on data from a large, prospective US national cohort study of patients initiating a new chemotherapy regimen for solid tumors and lymphoma.[10](#rth212284-bib-0010){ref-type="ref"} This risk model has been validated by independent investigators across a range of solid tumors[11](#rth212284-bib-0011){ref-type="ref"}, [12](#rth212284-bib-0012){ref-type="ref"}, [13](#rth212284-bib-0013){ref-type="ref"} and has been incorporated into clinical guidelines for VTE risk assessment.[14](#rth212284-bib-0014){ref-type="ref"}, [15](#rth212284-bib-0015){ref-type="ref"}, [16](#rth212284-bib-0016){ref-type="ref"}

Although validated and utilized among a range of solid tumors, this risk model has not been consistent in stratifying lung cancer patients for VTE risk,[17](#rth212284-bib-0017){ref-type="ref"}, [18](#rth212284-bib-0018){ref-type="ref"} especially in the era of targeted therapies and improved outcomes. Studies assessing epidermal growth factor receptor mutational status have demonstrated that positive status confers an almost 2‐fold increased risk of VTE.[17](#rth212284-bib-0017){ref-type="ref"} However, whether this association is related to the mutational status or the active intervention is unknown. Most recently, a global, prospective study (CANTARISK) showed that the risk model was not significantly associated with VTE in patients with non--small cell lung cancer.[19](#rth212284-bib-0019){ref-type="ref"}

Genomic predictors are widely used in oncology to inform prognosis and predict outcomes.[20](#rth212284-bib-0020){ref-type="ref"}, [21](#rth212284-bib-0021){ref-type="ref"}, [22](#rth212284-bib-0022){ref-type="ref"} For example, Oncotype DX uses a 21‐gene recurrence score to quantify distant recurrence risk and chemotherapy benefit in patients with breast cancer.[22](#rth212284-bib-0022){ref-type="ref"} Although various clinical predictors of VTE risk have been identified, the identification of biomarkers, such as genomic predictors with higher sensitivity and specificity are needed to better discriminate patients at increased risk of VTE. Herein, we use an RNA sequencing strategy of lung cancers to nominate biomarkers of cancer‐associated VTE.

2. METHODS {#rth212284-sec-0008}
==========

2.1. Identification of cohort and data collection {#rth212284-sec-0009}
-------------------------------------------------

We evaluated patients with lung cancer from a prospective institutional review board--approved registry at the Cleveland Clinic with available tissue from surgical excision of a primary lung mass between 2010 and 2015. We propensity‐matched patients on the basis of whether they developed VTE. VTE was defined as pulmonary embolism (PE), deep vein thrombosis (DVT), or catheter‐associated thrombus from 3 months prior to diagnosis to 24 months after diagnosis. Nine patients with VTE were propensity‐matched with 9 patients without VTE, with a score difference of \<5%. Patients were matched based on the following criteria: age at cancer diagnosis, sex, race, history of prior cancer, date of lung cancer diagnosis, stage, histology (classified as adenocarcinoma, squamous cell carcinoma, mixed small cell cancer/large cell neuroendocrine, or neuroendocrine tumor), number of lines of chemotherapy, and length of follow‐up. A logistic regression model including these variables was used to calculate the probability of VTE. This probability, or propensity score, was used to identify patients with VTE and without VTE with similar propensity scores, which resulted in the two groups being similar with respect to the matching characteristics. Patients were staged surgically if treated with initial surgery, or otherwise staged clinically per the American Joint Committee on Cancer 7th edition.[23](#rth212284-bib-0023){ref-type="ref"}

2.2. Sample preparation for RNA sequencing {#rth212284-sec-0010}
------------------------------------------

Tumors were isolated from surgical specimens. Representative histological sections demonstrated \>90% tumor purity in each sample tested. Nevertheless, contributions from stromal and immune cells likely contributed to the sequencing reads. RNA was collected from fresh frozen tumor samples using Allprep kit (Qiagen, Hilden, Germany) and subjected to quality control. Samples were checked using BioA, and libraries were prepared using TruSeq Total Stranded RNA‐RiboZero kit (Illumina, San Diego, CA, USA). Each library was quantified using Qubit and then pooled together. The library pool was quantified using quantitative polymerase chain reaction. The pool was then diluted to 4 nM and loaded on HiSeq at 12 pM. The run was performed using a full flow cell (2 lanes) PE 100; 5% PhiX was spiked in to check run quality (*Q* \> 30 = 96%). Six tumor samples (3 with VTE and 3 without VTE) had insufficient high‐quality RNA to proceed with sequencing analysis, due to tissue viability.

2.3. RNA sequencing {#rth212284-sec-0011}
-------------------

RNA was sequenced by HiSeq 2500 (Illumina, San Diego, CA, USA), resulting in paired 100‐nt reads. RNA reads were aligned to the hg19 genome assembly using MapSplice. Gene expression was quantified for transcript models corresponding to TCGA GAF2.13, using RSEM and normalized within sample to a fixed upper quartile. For gene‐level analyses, expression values of 0 were set to the overall minimum value, and all data were log2 transformed. The log2 fold change and adjusted *P* and *Q* values (using Benjamini‐Hochberg procedure) were calculated using linear models in combination with moderated t statistic.

2.4. Single‐sample GSEA and the information‐based association metric {#rth212284-sec-0012}
--------------------------------------------------------------------

From 23 710 genes, a total of 1037 genes had differential gene expression. GSEA was performed on these differentially expressed genes. Association between GSEA profiles for each gene set and binary categorical variables were determined using an information‐based similarity metric (RNMI). This quantity is obtained by estimating the differential mutual information[24](#rth212284-bib-0024){ref-type="ref"} between the VTE profile and each of the gene sets' GSEA profiles and then normalizing and rescaling it so that it is defined from 0 (no association) to 1 (perfect association). We estimate the differential mutual information using a kernel‐based method[25](#rth212284-bib-0025){ref-type="ref"} which places a Gaussian density centered at each data point and a width determined by a biased cross‐validation estimate.[25](#rth212284-bib-0025){ref-type="ref"}, [26](#rth212284-bib-0026){ref-type="ref"} The mutual information is then normalized[27](#rth212284-bib-0027){ref-type="ref"} using the joint entropy to better account for the intrinsic differences in entropy associated with each single‐sample GSEA profile. Nominal *P* values for the information‐based association metric scores between the gene sets/pathways and response scores were estimated using an empirical permutation test.

3. RESULTS AND DISCUSSION {#rth212284-sec-0013}
=========================

The characteristics of the study population are presented in Table [1](#rth212284-tbl-0001){ref-type="table"}. The final study population included 12 patients with lung tissue RNA samples meeting criteria for quality control (6 each with or without VTE) with a median age of 67 years (range, 48‐80), predominantly white (n = 10) males (n = 8) with stage IV disease (n = 7). Histology included 7 of 12 patients with adenocarcinoma, 3 squamous and 2 with mixed/other histology. Eight patients received first‐line chemotherapy with carboplatin doublet therapy. With respect to second‐line treatment, 2 patients received chemotherapy alone, 1 received chemotherapy plus immunotherapy, and 1 received immunotherapy alone. Eight patients (67%) did not receive second‐line treatment, and 9 patients (75%) did not receive third‐line treatment. Median follow‐up was 18 months (range, 1‐69).

###### 

Characteristics of propensity‐matched patient cohort

  Characteristics                                                              All patients, N = 12 (%)   Patients with VTE, n = 6 (%)   Patients without VTE, n = 6 (%)
  ---------------------------------------------------------------------------- -------------------------- ------------------------------ ---------------------------------
  Age, y                                                                                                                                 
  Median (range)                                                               67, (48‐80)                68                             66
  Gender                                                                                                                                 
  Male                                                                         8 (66.7)                   4 (66.7)                       4 (66.7)
  Female                                                                       4 (33.3)                   4 (66.7)                       4 (66.7)
  Race                                                                                                                                   
  White                                                                        10 (83.3)                  4 (66.7)                       6 (100)
  Black                                                                        2 (16.7)                   2 (33.3)                        
  History of coronary artery disease[a](#rth212284-note-0002){ref-type="fn"}   8 (75)                     5 (83.3)                       3 (66.7)
  Prior history of VTE                                                         1 (8.3)                    1 (16.7)                        
  Overall stage                                                                                                                          
  IA                                                                           1 (8.3)                    1 (16.7)                        
  IIA                                                                          1 (8.3)                                                   1 (16.7)
  IIIA                                                                         3 (25.0)                   1 (16.7)                       2 (33.3)
  IV                                                                           7 (58.3)                   4 (66.7)                       3 (66.7)
  Tumor stage                                                                                                                            
  T1b                                                                          2 (16.7)                   2 (33.3)                        
  T2a                                                                          3 (25.0)                   2 (33.3)                       1 (16.7)
  T2b                                                                          3 (25.0)                   1 (16.7)                       2 (33.3)
  T3                                                                           3 (25.0)                   1 (16.7)                       2 (33.3)
  T4                                                                           1 (8.3)                                                   1 (16.7)
  Nodal stage                                                                                                                            
  N0                                                                           3 (25.0)                   1 (16.7)                       2 (33.3)
  N1                                                                           2 (16.7)                   2 (33.3)                        
  N2                                                                           2 (16.7)                                                  2 (33.3)
  N3                                                                           4 (33.3)                   3 (50)                         1 (16.7)
  Distant metastasis                                                                                                                     
  M0                                                                           5 (41.7)                   2 (33.3)                       3 (50)
  M1b                                                                          7 (58.3)                   4 (66.7)                       3 (50)
  Tumor status                                                                                                                           
  Primary                                                                      8 (66.7)                   5 (83.3)                       3 (50)
  Recurrence                                                                   4 (33.3)                   1 (16.7)                       3 (50)
  Histology                                                                                                                              
  Adenocarcinoma                                                               7 (58.3)                   3 (50)                         4 (66.7)
  Squamous cell carcinoma                                                      3 (25.0)                   1 (16.7)                       2 (33.3)
  Mixed[b](#rth212284-note-0003){ref-type="fn"}                                1 (8.3)                    1 (16.7)                        
  Other (neuroendocrine)                                                       1 (8.3)                    1 (16.7)                        
  Treatment received (first line)                                                                                                        
  Carboplatin doublet therapy                                                  8 (66.7)                   4 (66.7)                       4 (66.7)
  Immunotherapy                                                                1 (8.3)                                                   1 (16.7)
  None                                                                         3 (25.0)                   2 (33.3)                       1 (16.7)
  Treatment received (second line)                                                                                                       
  Chemotherapy                                                                 3 (25.0)                   2 (33.3)                       1 (16.7)
  Carboplatin doublet therapy                                                                                                            1 (16.7)
  Pemetrexed/bevacizumab                                                                                  1 (16.7)                        
  Irinotecan                                                                                              1 (16.7)                        
  Immunotherapy (Nivolumab)                                                    1 (8.3)                                                   1 (16.7)
  None                                                                         8 (66.7)                   4 (66.7)                       4 (66.7)
  Treatment received (third line)                                                                                                        
  Chemotherapy                                                                 1 (8.3)                                                   1 (16.7)
  Immunotherapy (Nivolumab)                                                    2 (16.7)                   1 (16.7)                       1 (16.7)
  None                                                                         9 (75.0)                   5 (83.3)                       1 (16.7)
  Length of follow‐up, mo                                                                                                                
  Median (range)                                                               18, (1‐69)                 19.5                           18

Defined as stable angina, acute coronary syndrome, and sudden cardiac death.

Mixed histology signifies combined small cell lung cancer and large cell neuroendocrine.
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Of 6 patients without VTE, 3 had a history of coronary artery disease, and no patients had prior history of VTE. Of 6 patients with VTE, 5 (83%) had a history of coronary artery disease, and 1 (17%) had prior history of VTE. Two (33%) had lower extremity DVT, 3 (50%) had PE, and 1 patient (17%) had an extensive catheter‐associated thrombus in the superior vena cava, extending into the right atrium. Two (33%) VTEs were discovered at diagnosis, 1 before treatment, 1 during treatment, and 2 during treatment break. Five patients developed VTE within 1 year of cancer diagnosis, and 1 patient developed VTE about 1.5 years from diagnosis. Specifically, patients developed VTE at days −5, −62, +152, +340, and +566 from respective date of cancer diagnosis.

We identified 1037 genes with differential gene expression. In patients with VTE, 869 genes were overexpressed and 168 were underexpressed compared to patients without VTE (Figure [1](#rth212284-fig-0001){ref-type="fig"}). Of these, 276 genes with statistically significant (*Q* \< 0.05) differential expression were identified, which were composed of 241 genes that were overexpressed in patients with lung cancer with VTE and 35 genes that were underexpressed. When gene expression was limited to those that included log (fold change) of +3 or greater and −3 or lower, a total of 146 genes were identified; 130 of which were overexpressed in patients with lung cancer with VTE and 16 genes that were underexpressed. We further limited genes to include a log (fold change) of +4 or greater and −3 or lower, and to include only those with *Q* \< 0.05. This criterion established a total gene population of 27 genes, 15 of which were overexpressed in patients with lung cancer with VTE, and 12 genes that were underexpressed (Table [2](#rth212284-tbl-0002){ref-type="table"}).

![Scatter plot highlighting differential gene expression (1037 genes) from RNA sequencing for patients with lung cancer with VTE compared to those without VTE. Values in red denote avidly overexpressed genes, up to 4‐fold. Positive log values (869 genes) represent overexpressed genes, while negative values (168 genes) represent underexpressed genes in patients with VTE. VTE, venous thromboembolism](RTH2-4-117-g001){#rth212284-fig-0001}

###### 

Genes with differential expression in lung cancer patients with VTE

  Gene        Full gene name                                                     *Log* (fold change)   *Q* value   Function
  ----------- ------------------------------------------------------------------ --------------------- ----------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  *CECR1*     Cat eye syndrome chromosome region, candidate 1                    4.9                   0.000008    Participates in cell proliferation and differentiation
  *SYT14*     Synaptotagmin 14                                                   4.9                   0.00001     Mediates membrane trafficking in synaptic transmission
  *JSRP1*     Junctional sarcoplasmic reticulum protein 1                        4.8                   0.00002     Excitation‐contraction coupling at the sarcoplasmic reticulum, regulates calcium influx and efflux
  *MIAT*      Myocardial infarction associated transcript                        4.8                   0.000003    Myocardial infarction transcript
  *SHC4*      Squalene‐hopene cyclase adaptor protein 4                          4.6                   0.00003     Ras activating pathway
  *LSAMP*     Limbic system associated membrane protein                          4.4                   0.0002      Mediates selective neuronal growth and axon targeting
  *ASTN1*     Astrotactin 1                                                      4.3                   0.0004      Neuronal adhesion molecule
  *IGLL5*     Immunoglobulin lambda‐like polypeptide 5                           4.3                   0.0004      Protein coding
  *FAM107A*   Family with sequence similarity 107 member A                       4.3                   0.0004      Associated with tumor development
  *CR1*       Complement C3b/C4b receptor 1                                      4.2                   0.0005      Receptor for activated complement
  *PEX5L*     Peroxisomal biogenesis factor 5 like                               4.2                   0.0005      Hyperpolarization‐activated cyclic nucleotide‐gated channels
  *TNFSF8*    Tumor necrosis factor superfamily member 8                         4.1                   0.0008      Induces T cell proliferation or death
  *PROX1*     Prospero homeobox 1                                                4.1                   0.0008      Transcription factor involved in developmental processes such as cell fate determination, gene transcriptional regulation, and progenitor cell regulation
  *NTM*       Neurotrimin                                                        4.1                   0.0006      Promotes neurite adhesion
  *ATP8A2*    ATPase phospholipid transporting 8A2                               4.0                   0.001       Involved in lipid flipping
  *SYT12*     Synaptotagmin 12                                                   −3.0                  0.02        Mediates calcium‐dependent regulation of membrane trafficking in synaptic transmission
  *LMX1B*     LIM homeobox transcription factor 1 beta                           −3.1                  0.02        Transcription factor
  *MIR31HG*   MIR31 host gene                                                    −3.1                  0.02        Involved in cellular pluripotency, regulates differentiation of myoblasts and other tissue; repress transcription of genes involved in cell senescence
  *EPHB6*     Ephrin type‐B receptor 6                                           −3.3                  0.009       Cell adhesion and migration
  *KLHL35*    Kelch‐like family member 35                                        −3.3                  0.0002      Protein coding
  *IRX4*      Iroquois homeobox 4                                                −3.4                  0.01        Cell differentiation, heart development, multicellular organism development
  *TGM1*      Transglutaminase 1                                                 −3.4                  0.004       Crosslinking of proteins
  *DSG1*      Desmoglein 1                                                       −3.5                  0.009       Component of desmosome
  *TRPV6*     Transient receptor potential cation channel subfamily V member 6   −3.5                  0.007       Involved in calcium channel function
  *ALOX12B*   Arachidonate 12‐lipoxygenase, 12R type                             −3.6                  0.005       Conversion of arachidonic acid
  *VSIG10L*   V‐set and immunoglobulin domain containing 10 like                 −3.6                  0.0001      Protein coding
  *EN1*       Engrailed homeobox 1                                               −4.1                  0.0008      Cell development and differentiation
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The most highly overexpressed genes were *CECR1* and *MIAT*. *CECR1* (4.9‐fold elevation, *Q* = 0.000008) regulates cell proliferation and differentiation, while *MIAT* (4.8‐fold elevation, *Q* = 0.000003) is linked to cardiac thrombosis. *SHC4* (4.6, *Q* = 0.00003) is a gene that activates both Ras‐dependent and Ras‐independent pathways. We also identified genes involved in inflammatory pathways, which regulate the innate immune system, notably, *NLRP14* (3.8, *Q* = 0.0001), *CLNK* (3.6, *Q* = 0.005), *IL5RA* (3.6, *Q* = 0.006), *XCL1* (3.5, *Q* = 0.008), *IL16* (3.4, *Q* = 0.002), and *CCR6* (3.0, *Q* = 0.02), as well as genes involved in complement activation, *CR1* (4.2, *Q* = 0.0005).

GSEA showed gene sets associated with innate immunity and inflammatory pathways, which included IL2‐STAT5 signaling, IL6‐JAK‐STAT3 signaling, interferon‐ response, complement, and inflammatory response (Table [3](#rth212284-tbl-0003){ref-type="table"}). Conversely, genes associated with apoptosis pathways, myogenesis pathways, and epithelial mesenchymal pathways were underexpressed.

###### 

Gene set enrichment analysis (GSEA)

  Associated gene set pathways        Normalized *P* value   FDR *Q* value
  ----------------------------------- ---------------------- ---------------
  IL2_STAT5_SIGNALING                 0.11                   0.44
  ALLOGRAFT_REJECTION                 0.03                   0.25
  IL6_JAK_STAT3_SIGNALING             0.50                   0.68
  INTERFERON_GAMMA_RESPONSE           0.26                   0.64
  KRAS_SIGNALING_UP                   0.42                   0.67
  COMPLEMENT                          0.59                   0.67
  INFLAMMATORY_RESPONSE               0.40                   0.77
  APICAL_JUNCTION                     0.85                   0.84
  SPERMATOGENESIS                     0.97                   0.98
  EPITHELIAL_MESENCHYMAL_TRANSITION   0.76                   0.89
  MYOGENESIS                          0.69                   1
  COAGULATION                         0.70                   1
  KRAS_SIGNALING_DN                   0.40                   1
  TNFA_SIGNALING_VIA_NFKB             0.48                   1
  APOPTOSIS                           0.08                   0.73

FDR, false discovery rate.
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Several genes identified in our study are consistent with prior genes identified in arterial thrombosis and inflammatory response, for example, *MIAT* (myocardial infarction‐associated transcript) and *NLRP14* (nucleotide‐binding oligomerization domain, leucine rich repeat and pyrin domain containing 14). Recent studies have shown that *MIAT* is elevated and associated in patients with acute myocardial infarction (*P* \< .001) in the peripheral blood and overexpressed in atherosclerotic plaques in patients undergoing coronary artery bypass surgery.[28](#rth212284-bib-0028){ref-type="ref"}, [29](#rth212284-bib-0029){ref-type="ref"}, [30](#rth212284-bib-0030){ref-type="ref"} Additionally, serum levels of *MIAT* were positively associated with percentage of lymphocytes and negatively with neutrophils and platelet count, suggesting an inflammatory component.[29](#rth212284-bib-0029){ref-type="ref"} Five patients with VTE and 3 patients without VTE had a history of CAD; *MIAT* was upregulated only in patients with VTE, suggesting that *MIAT* may be specific for VTE in our cohort, although confirmation is necessary. Additionally, recent studies have identified gene expression profiles in patients with atherosclerosis that do not possess *MIAT*.[31](#rth212284-bib-0031){ref-type="ref"}, [32](#rth212284-bib-0032){ref-type="ref"} Similarly, *NLRP14* is a member of *NLRP3* genes responsible for activation of the inflammasome complex, which may be associated with thrombotic events.[33](#rth212284-bib-0033){ref-type="ref"}, [34](#rth212284-bib-0034){ref-type="ref"} These data are consistent with the knowledge that inflammatory states such as inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus are prothrombotic.[35](#rth212284-bib-0035){ref-type="ref"}, [36](#rth212284-bib-0036){ref-type="ref"}, [37](#rth212284-bib-0037){ref-type="ref"}

We identified several gene sets that implicated Kras signaling as associated with a higher risk of developing VTE. This finding is consistent with a study demonstrating metastatic colorectal patients (N = 172) with tumor mutant KRAS status (N = 65) were associated with a 14.5% increased risk of VTE.[38](#rth212284-bib-0038){ref-type="ref"} If validated, Kras could become a tumor‐based biomarker for assessing VTE risk; the precise means by which activation of Kras can increase the risk of thrombosis remains unclear.

A recent study identified differential gene expression in patients with colorectal cancer (CRC) with VTE only before CRC diagnosis and around the time (±3 months) of CRC diagnosis.[39](#rth212284-bib-0039){ref-type="ref"} This study found 30 differentially expressed genes and performed Ingenuity pathway analysis on the top 10 genes in patients with VTE. This study also found inflammatory pathway associated with VTE and several shared genes with our study: *SBSPON, DEFA5, PTPRR, SORBS1*. Another study identified similar genes and pathways in patients with no cancer with single and recurrent VTE. Both cohorts had differential expression of immune and inflammatory pathways, specifically interferon‐γ and STAT3, and cancer pathway RAS, which is consistent with our study.[40](#rth212284-bib-0040){ref-type="ref"} Of the 36 genes presented in this study, overlap of inflammatory genes *LTB* and *SLC7A11* were identified. An additional study identified 559 and 294 differentially expressed genes in patients with no cancer with recurrent and single VTE, respectively. Of these, 202 upregulated and 58 downregulated genes overlapped between the two groups.[41](#rth212284-bib-0041){ref-type="ref"} Leukocyte transendothelial migration and JAK‐STAT3 signaling pathways were associated with recurrent VTE, the latter of which is consistent with our study. In both patients with cancer and patients without cancer with VTE, inflammatory and immune pathways were identified across several studies, suggesting that these pathways are involved in thrombosis.

A limitation of this study is our sample size, which limited the power of this analysis. We were limited by tissue quality, as several tissue samples were of insufficient quality for RNA sequencing. Additionally, stromal cells and immune cells may have contributed to the sequencing reads, although representative histological sections demonstrated \>90% tumor purity in each sample tested. Bulk sequencing provides insight to the tumor microenvironment and can provide additional knowledge to the function of immune cells in relation to VTE events. The results should be considered provisional, requiring validation through replication in independent study populations and demonstration of biologic plausibility.

In conclusion, to our knowledge, this study is the first to employ whole transcriptome RNA profiling strategy in lung cancer to identify differentially expressed genes and possible pathways that may guide therapeutic targets for cancer‐associated VTE in the future.
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